{"id":"W2142226415","doi":"10.1016/s1470-2045(15)70064-1","title":"Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":285,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"Fudan University; Natural Science Foundation of Shanghai; Eli Lilly and Company","keywords":"Gemcitabine; Medicine; Internal medicine; Regimen; Metastatic breast cancer; Oncology; Breast cancer; Clinical endpoint; Triple-negative breast cancer; Chemotherapy; Cisplatin; Paclitaxel; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002051767,0.002834687,0.003940663,0.0006249475,0.0005353145,0.001610868,0.001575947,0.002558822,0.01135447],"category_scores_gemma":[0.002216277,0.0009453403,0.003236629,0.0006771371,0.001680087,0.001733706,0.0007464297,0.006259168,0.002065623],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001423248,"about_ca_system_score_gemma":0.001691424,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002015188,"about_ca_topic_score_gemma":0.004969476,"domain_scores_codex":[0.9992957,0.0003809555,0.00002932032,0.000130216,0.00005485043,0.0001089997],"domain_scores_gemma":[0.9989209,0.0003070927,0.0001942422,0.00007696392,0.00005009374,0.000450735],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9859081,0.003074926,0.0001768399,0.0003594229,0.0005388072,0.00002327845,0.00003660754,0.0003592541,0.0009662962,0.00008915281,0.0008997852,0.007567499],"study_design_scores_gemma":[0.9672455,0.03133161,0.0004682394,0.00002233177,0.0001979868,0.00001778654,0.00001246927,0.0002220523,0.0001097116,0.0001117187,0.000250122,0.00001049818],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9818212,0.004800664,0.000905894,0.001569951,0.001227346,0.004604789,0.001914056,0.0002797759,0.002876441],"genre_scores_gemma":[0.9748119,0.004792084,0.002424568,0.002405799,0.0007384035,0.004599624,0.002650733,0.00009041167,0.007486457],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01135447,"threshold_uncertainty_score":0.03798449,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2756851049856489,"score_gpt":0.4983969678085888,"score_spread":0.2227118628229399,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}